Solid Biosciences Inc.
Clinical trials sponsored by Solid Biosciences Inc., explained in plain language.
A gene therapy company focused on neuromuscular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy trial aims to slow duchenne muscular dystrophy in boys Results expected Oct 2026 (estimated)
- Gene therapy trial aims to stop duchenne in its tracks Results expected May 2027 (estimated)
- Gene therapy trial aims to tame deadly heart rhythms Results expected Jun 2027 (estimated)
-
Gene therapy hope for rare nerve disease enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a gene therapy called SGT-212 for Friedreich's ataxia, a rare genetic disease that damages the nervous system. Ten adults with the condition will receive the therapy through an injection into the brain and a vein. The main goal is to see if it is…
Phase 1 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Gene therapy trial aims to help boys with duchenne walk stronger
Disease control Recruiting nowThis study tests a one-time gene therapy called SGT-003 in 80 boys with Duchenne muscular dystrophy who can still walk. The goal is to see if it helps them move better, like standing up faster and climbing stairs. Participants will receive either the therapy or a placebo first, t…
Phase 3 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Gene therapy trial aims to tame deadly heart rhythms
Disease control Recruiting nowThis early-stage trial tests a single dose of SGT-501, a gene therapy given by IV, in 18 people with a rare inherited heart condition called CPVT that can cause dangerous fast heartbeats during exercise or stress. The main goal is to check safety and find the right dose in adults…
Phase 1 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Gene therapy trial aims to stop duchenne in its tracks
Disease control Recruiting nowThis study tests a single dose of SGT-003, a gene therapy that delivers a working version of the dystrophin gene to muscle cells. About 60 boys with Duchenne muscular dystrophy, aged from infancy to under 18, will receive the treatment and be followed for 5 years. The goal is to …
Phase 1/2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC